A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

• Status: Completed
• Trial end date: 2021-03-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• Have histological or cytological evidence of a diagnosis of platinum sensitive small cell lung cancer that is extensive stage.

• Have adequate organ function.

• Have a performance status (PS) of ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.

• Have discontinued previous treatments for cancer.

• Are able to swallow capsules.

Exclusion Criteria:

• Currently enrolled in a clinical study.

• Have a serious concomitant systemic disorder.

• Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.

• Have a significant cardiac condition.

• Have previously received an aurora kinase inhibitor.